About Bridge Biotherapeutics
Bridge Biotherapeutics is a publicly listed company based in Seongnam-si (South Korea) founded in 2015, and was acquired by Parataxis Capital in June 2025. Small molecule therapeutics are developed for treating various diseases. Bridge Biotherapeutics has raised $10 million across 2 funding rounds from investors including KB Investment, LB Investment and HB Investment. The company has 36 employees. Its focus areas include Life Sciences, Immunology, Drugs and Inflammatory Diseases. Its legal entity is BRIDGE BIOTHERAPEUTICS INC.
Company details
Bridge Biotherapeutics was founded in 2015 in Seongnam-si, South Korea, within the biotechnology sector. Small molecule-based therapeutics are developed by the company for diseases including ulcerative colitis, fibrotic conditions, and cancers. The pipeline features BBT-401, a pellino-1 inhibitor in Phase 2 trials for ulcerative colitis, and BBT-877, an autotaxin inhibitor in Phase 2 trials for idiopathic pulmonary fibrosis. Additional candidates are maintained in preclinical and early development stages.
- Headquarters Seongnam-si, South Korea
- Employees 36
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website bridgebiorx.com
- Social LinkedIn X Facebook
- Acquired by Parataxis Capital (Jun 2025)
- Legal Name Parataxis Korea, Inc.
- Annual Revenue$6.23 K (USD)313.21as on Dec 31, 2025
- Net Profit-$21.47 M (USD)-56.89as on Dec 31, 2025
- EBITDA-$9.67 M (USD)26.66as on Dec 31, 2025
- Total Equity Funding$10M (USD)
in 2 rounds
- Latest Funding Round$10M (USD), Series A
Jul 2017
- InvestorsKB Investment
& 6 more
- Employee Count36
- Acquired byParataxis Capital
(Jun 2025)
Funding Insights of Bridge Biotherapeutics
Bridge Biotherapeutics has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10M
- Total Rounds 2
- Last Round Series A — $10M
- Investors Count 6
All 2 funding rounds of Bridge Biotherapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $10M | Series A | – | DAOL Investment, Lifecore Partners | |
| Jun 2015 | Seed | – | – |
7 investors in total: 7 institutional.
Investors in Bridge Biotherapeutics
Bridge Biotherapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include KB Investment, LB Investment and HB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund | daolinvestment.com | Seongnam-si, South Korea | ||
Growth-stage private equity investments are targeted across multiple sectors. | 1996 | lbinvestment.com | Seoul, South Korea | |
| lifecorepartners.com | ||||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Venture capital firm focused on multiple sectors | 1999 | hbvc.co.kr | Seoul, South Korea | |
Parataxis Capital is focused on digital asset investment advisory. | 2019 | parataxis.io | New York, United States | |
Venture capital investments are provided to innovative companies by SV Investment. | svinvestment.co.kr | Seoul, South Korea |
Investor details for Bridge Biotherapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bridge Biotherapeutics
7 people are tracked at Bridge Biotherapeutics (7 in leadership); the tracked headcount is 36.
| Name | Role | Group |
|---|---|---|
Yunseon Chong | Director BD | Leadership |
Hyung Eun Kim | Director, Head Of Pharmacovigilance | Leadership |
진혁 정 | Head Of Research | Leadership |
Mikyoung Chang | Director, Scientific Affairs/ Scientific Liaison | Leadership |
James Jungkue Lee | CEO | Leadership |
Joengbin Ahn | Director Of Communications | Leadership |
Sujin Jung | Vp, Head Of Clinical Development And Operations | Leadership |
Complete people profiles for Bridge Biotherapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bridge Biotherapeutics
Bridge Biotherapeutics is a publicly listed company on the KRX with ticker symbol 288330 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date20 Dec 2019
- Listed onKRX: 288330
- Listed entityParataxis Korea, Inc.
- Exchange sectorHealth technology
- ISINKR7288330004
- Share price416.00 KRW (-3.03% on the day) · 2026-04-20
- Market capitalisation44,127,398,682.00 KRW
- EPS (diluted, trailing year)-407.88 KRW
- Volume (last session)7,390,375
- Analyst consensusNo rating
Financials of Bridge Biotherapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 9.0M KRW | -31.00B KRW | -13.96B KRW |
| 2024 | 2.2M KRW | -19.76B KRW | -19.04B KRW |
| 2023 | 100.0M KRW | -42.32B KRW | -41.36B KRW |
| 2022 | 3.02B KRW | -41.70B KRW | -42.42B KRW |
| 2021 | 1.92B KRW | -26.28B KRW | -26.01B KRW |
Detailed financial statements for Bridge Biotherapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Bridge Biotherapeutics
5 dated milestones of Bridge Biotherapeutics across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Bridge Biotherapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Parataxis Capital.
Web traffic of Bridge Biotherapeutics
The website of Bridge Biotherapeutics (bridgebiorx.com) receives about 3.7K visits a month and ranks #4,599,608 among all websites worldwide, #5,493 in Biotechnology and Pharmaceuticals.
- Monthly visits3.7K
▲ 10.3% vs previous month
- Unique visitors1.4K
per month
- Global rank#4,599,608
among all websites
- Category rank#5,493
Health · Biotechnology and Pharmaceuticals
- Bounce rate31%
- Pages per visit2.2
- Average visit12 min 43 sec
- DevicesDesktop 32% · Mobile 68%
Websites whose visitors overlap most with Bridge Biotherapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
newsmp.com | newsmp.com | 100% | #330,463 | – | |
| biotimes.co.kr | 100% | #456,742 | View details | ||
thebionews.net | thebionews.net | 100% | #353,035 | – | |
| pharmnews.com | 100% | #274,610 | View details | ||
| hitnews.co.kr | 100% | #146,502 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Bridge Biotherapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bridge Biotherapeutics
Complete news archive for Bridge Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bridge Biotherapeutics
Bridge Biotherapeutics was founded in 2015.
Bridge Biotherapeutics is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Bridge Biotherapeutics is a funded company, having raised a total of $10M across 2 funding rounds to date.
Bridge Biotherapeutics has 36 employees.
Annual revenue of Bridge Biotherapeutics is $6.23K as on Dec 31, 2025.
Bridge Biotherapeutics was founded in 2015 in Seongnam-si, South Korea, within the biotechnology sector. Small molecule-based therapeutics are developed by the company for diseases including ulcerative colitis, fibrotic conditions, and cancers. The pipeline features BBT-401, a pellino-1 inhibitor in Phase 2 trials for ulcerative colitis, and BBT-877, an autotaxin inhibitor in Phase 2 trials for idiopathic pulmonary fibrosis. Additional candidates are maintained in preclinical and early development stages.
Yes, Bridge Biotherapeutics is publicly traded on KRX under the ticker symbol 288330.
Bridge Biotherapeutics has 7 investors. Key investors include KB Investment, LB Investment, HB Investment, DAOL Investment, and Lifecore Partners.
Bridge Biotherapeutics operates through Bridge Biotherapeutics Inc..
Yes. Bridge Biotherapeutics was acquired by Parataxis Capital in June 2025.